270 related articles for article (PubMed ID: 19248684)
1. MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.
Cahill DP; Codd PJ; Batchelor TT; Curry WT; Louis DN
Clin Neurosurg; 2008; 55():165-71. PubMed ID: 19248684
[No Abstract] [Full Text] [Related]
2. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Cahill DP; Levine KK; Betensky RA; Codd PJ; Romany CA; Reavie LB; Batchelor TT; Futreal PA; Stratton MR; Curry WT; Iafrate AJ; Louis DN
Clin Cancer Res; 2007 Apr; 13(7):2038-45. PubMed ID: 17404084
[TBL] [Abstract][Full Text] [Related]
3. [Temozolomide in patients with a glioblastoma multiforme: new developments].
Bromberg JE; Postma TJ
Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1376-8. PubMed ID: 15997689
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant temozolomide: how long and how much?
Franceschi E; Tosoni A; Brandes AA
Expert Rev Anticancer Ther; 2008 May; 8(5):663-5. PubMed ID: 18471038
[No Abstract] [Full Text] [Related]
5. Treatment of brain tumors.
Seiter K
N Engl J Med; 2005 Jun; 352(22):2350-3; author reply 2350-3. PubMed ID: 15938012
[No Abstract] [Full Text] [Related]
6. Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis?
Peca C; Pacelli R; Elefante A; Del Basso De Caro ML; Vergara P; Mariniello G; Giamundo A; Maiuri F
Clin Neurol Neurosurg; 2009 May; 111(4):331-4. PubMed ID: 19117668
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide in glioblastoma multiforme of the elderly.
Brandes AA; Vastola F; Basso U; Pasetto LM; Ermani M; Berti F; Rotilio A; Amistà P; Scienza R; Monfardini S
Tumori; 2002; 88(1 Suppl 1):S69-70. PubMed ID: 11989929
[No Abstract] [Full Text] [Related]
8. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.
Yip S; Miao J; Cahill DP; Iafrate AJ; Aldape K; Nutt CL; Louis DN
Clin Cancer Res; 2009 Jul; 15(14):4622-9. PubMed ID: 19584161
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme.
Johannessen TC; Bjerkvig R
Expert Rev Anticancer Ther; 2012 May; 12(5):635-42. PubMed ID: 22594898
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma.
Spiegl-Kreinecker S; Pirker C; Marosi C; Buchroithner J; Pichler J; Silye R; Fischer J; Micksche M; Berger W
Br J Cancer; 2007 Mar; 96(6):960-9. PubMed ID: 17342095
[TBL] [Abstract][Full Text] [Related]
11. [Side effects of temozolomide treatment in patient with glioblastoma multiforme--case study].
Łata S; Molczyk A
Przegl Lek; 2010; 67(5):445-6. PubMed ID: 20684359
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas.
Chamberlain MC
Expert Rev Neurother; 2010 Oct; 10(10):1537-44. PubMed ID: 20925470
[TBL] [Abstract][Full Text] [Related]
13. Adding concomitant and adjuvant temozolomide to radiotherapy does not reduce health-related quality of life in people with glioblastoma.
Hamilton DA
Cancer Treat Rev; 2006 Oct; 32(6):483-6. PubMed ID: 16730911
[No Abstract] [Full Text] [Related]
14. [Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma].
Malkoun N; Fotso MJ; Cartier L; Forest F; Auberdiac P; Chargari C; Thorin J; Pacaut C; Peoc'h M; Nuti C; Schmitt T; Magné N
Cancer Radiother; 2011 Jun; 15(3):202-7. PubMed ID: 21450506
[TBL] [Abstract][Full Text] [Related]
15. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for brain tumors--a new beginning.
DeAngelis LM
N Engl J Med; 2005 Mar; 352(10):1036-8. PubMed ID: 15758016
[No Abstract] [Full Text] [Related]
17. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
Brandes AA; Franceschi E; Tosoni A; Benevento F; Scopece L; Mazzocchi V; Bacci A; Agati R; Calbucci F; Ermani M
Cancer; 2009 Aug; 115(15):3512-8. PubMed ID: 19514084
[TBL] [Abstract][Full Text] [Related]
18. The evolution of chemoradiation for glioblastoma: a modern success story.
Mirimanoff RO
Curr Oncol Rep; 2006 Jan; 8(1):50-3. PubMed ID: 16464403
[TBL] [Abstract][Full Text] [Related]
19. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
Chamberlain MC; Tsao-Wei DD
Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
[TBL] [Abstract][Full Text] [Related]
20. Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide.
Stuplich M; Hadizadeh DR; Kuchelmeister K; Scorzin J; Filss C; Langen KJ; Schäfer N; Mack F; Schüller H; Simon M; Glas M; Pietsch T; Urbach H; Herrlinger U
J Clin Oncol; 2012 Jul; 30(21):e180-3. PubMed ID: 22689800
[No Abstract] [Full Text] [Related]
[Next] [New Search]
